Buy Rating Affirmed for Lantheus Holdings With Enhanced Revenue Projections and Strategic Expansion
Barclays Adjusts Price Target on Fluor to $45 From $39, Maintains Equalweight Rating
Fluor Analyst Ratings
Barclays Sticks to Its Hold Rating for Fluor (FLR)
Fluor Analyst Ratings
Keybanc Upgrades Fluor to Overweight, Announces $57 Price Target
Sprouts Farmers Market Analyst Ratings
Insmed Analyst Ratings
Barclays Keeps Their Buy Rating on Insmed (INSM)
Analyst Ratings For Abercrombie & Fitch
Abercrombie & Fitch Analyst Ratings
Lantheus Holdings Analyst Ratings
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Truist Securities Adjusts Price Target on Lantheus Holdings to $141 From $96, Maintains Buy Rating
Lantheus Buy Rating Affirmed Amid Favorable CMS Changes and Strong Market Position
Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $102
Goldman Sachs Adjusts Price Target on Sprouts Farmers Market to $89 From $78, Maintains Buy Rating
FTAI Aviation Downgraded at Wolfe Research
Sprouts Farmers Market Analyst Ratings